Published in Immunotherapy Weekly, May 16th, 2001
Dr. David M. Goldenberg, Immunomedics, described progress being made in collaboration with its affiliated company, IBC Pharmaceuticals, LLC (IBC), with the next-generation method of pretargeting involving bispecific, or two-armed, antibodies. IBC has broad patent coverage for the pretargeting methodology, referred to as Affinity Enhancement System, or AES, in the scientific literature.
Goldenberg explained that "conventional methods have involved directly attaching therapeutic drugs or isotopes to antibodies, and these...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.